Fractyl Laboratories said today that it raised $44 million in a Series D round, led by an undisclosed investor and first-time investors GV, True Ventures and the IDO Fund.
Returning investors included Deerfield Management Company, Bessemer Venture Partners and others. The company said it plans to use the round’s proceeds to fund the continued development of its Revita duodenal mucosal resurfacing procedure for people with Type II diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Fractyl raises $44m Series D for Revita DMR tech appeared first on MassDevice.
from MassDevice http://ift.tt/2i1NTSx
Cap comentari:
Publica un comentari a l'entrada